Načítá se...
The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study
INTRODUCTION: We evaluated the predictive factors which affect the efficacy of naftopidil 50 mg/day therapy and dose increase therapy to administration of 75 mg/day after an initial dose of 50 mg/day. MATERIALS AND METHODS: A total of 92 patients with male lower urinary tract symptoms/benign prostat...
Uloženo v:
| Vydáno v: | Urol Ann |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Medknow Publications & Media Pvt Ltd
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532895/ https://ncbi.nlm.nih.gov/pubmed/28794594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/UA.UA_23_17 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|